DCTD

Summary

DCTD (dCMP deaminase, HGNC:2710) is a protein-coding gene on chromosome 4q35.1, encoding Deoxycytidylate deaminase (P32321). Catalyzes the deamination of dCMP to dUMP, providing the nucleoside monophosphate substrate for the thymidylate synthase/TYMS.

The protein encoded by this gene catalyzes the deamination of dCMP to dUMP, the nucleotide substrate for thymidylate synthase. The encoded protein is allosterically activated by dCTP and inhibited by dTTP, and is found as a homohexamer. This protein uses zinc as a cofactor for its activity. Two transcript variants encoding different isoforms have been found for this gene.

Source: NCBI Gene 1635 — RefSeq curated summary.

At a glance

• GWAS associations: 14
• Clinical variants (ClinVar): 45 total
• Druggable target: yes
• MANE Select transcript: NM_001921

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:2710
Approved symbol	DCTD
Name	dCMP deaminase
Location	4q35.1
Locus type	gene with protein product
Status	Approved
Ensembl gene	ENSG00000129187
Ensembl biotype	protein_coding
OMIM	607638
Entrez	1635

Gene structure

Transcript identifiers

Ensembl transcripts: 41 — 34 protein_coding, 6 nonsense_mediated_decay, 1 protein_coding_CDS_not_defined

ENST00000357067, ENST00000438320, ENST00000500813, ENST00000503182, ENST00000503820, ENST00000503988, ENST00000507543, ENST00000507631, ENST00000508994, ENST00000509218, ENST00000509757, ENST00000510307, ENST00000510370, ENST00000512766, ENST00000513348, ENST00000513383, ENST00000514754, ENST00000908122, ENST00000908123, ENST00000908124, ENST00000908125, ENST00000908126, ENST00000908127, ENST00000908128, ENST00000908129, ENST00000908130, ENST00000908131, ENST00000908132, ENST00000926931, ENST00000926932, ENST00000926933, ENST00000926934, ENST00000926935, ENST00000926936, ENST00000926937, ENST00000926938, ENST00000926939, ENST00000926940, ENST00000949230, ENST00000949231, ENST00000949232

RefSeq mRNA: 9 — MANE Select: NM_001921 NM_001012732, NM_001351743, NM_001351744, NM_001351745, NM_001351747, NM_001351748, NM_001351750, NM_001351753, NM_001921

CCDS: CCDS34108, CCDS3831

Canonical transcript exons

ENST00000438320 — 6 exons

Exon	Start	End
ENSE00002040393	182917311	182917386
ENSE00003500086	182915461	182915575
ENSE00003525191	182914923	182915058
ENSE00003674419	182890091	182891477
ENSE00003694327	182893031	182893127
ENSE00003786290	182894489	182894605

Expression profiles

Bgee: expression breadth ubiquitous, 285 present calls, max score 97.81.

FANTOM5 (CAGE): breadth ubiquitous, TPM avg 38.2791 / max 177.2784, expressed in 1815 samples.

FANTOM5 promoters (6 alternative TSS)

Promoter ID	TPM avg	Samples expressed
55081	31.4684	1813
55083	4.9256	1697
55079	1.0831	784
55082	0.4609	233
55084	0.2244	83
55080	0.1168	28

Top tissues by expression

293 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
stromal cell of endometrium	CL:0002255	97.81	gold quality
right adrenal gland	UBERON:0001233	96.80	gold quality
left adrenal gland	UBERON:0001234	96.61	gold quality
gall bladder	UBERON:0002110	96.51	gold quality
right adrenal gland cortex	UBERON:0035827	96.50	gold quality
islet of Langerhans	UBERON:0000006	96.43	gold quality
adrenal tissue	UBERON:0018303	96.40	gold quality
left adrenal gland cortex	UBERON:0035825	96.29	gold quality
adrenal gland	UBERON:0002369	95.98	gold quality
left lobe of thyroid gland	UBERON:0001120	95.95	gold quality
thyroid gland	UBERON:0002046	95.67	gold quality
adrenal cortex	UBERON:0001235	95.64	gold quality
right lobe of thyroid gland	UBERON:0001119	95.52	gold quality
endocervix	UBERON:0000458	94.94	gold quality
left ovary	UBERON:0002119	94.77	gold quality
esophagus mucosa	UBERON:0002469	94.74	gold quality
body of pancreas	UBERON:0001150	94.71	gold quality
body of stomach	UBERON:0001161	94.71	gold quality
pancreas	UBERON:0001264	94.66	gold quality
right coronary artery	UBERON:0001625	94.56	gold quality
right ovary	UBERON:0002118	94.45	gold quality
thoracic aorta	UBERON:0001515	94.33	gold quality
ascending aorta	UBERON:0001496	94.31	gold quality
C1 segment of cervical spinal cord	UBERON:0006469	94.21	gold quality
right lobe of liver	UBERON:0001114	94.14	gold quality
descending thoracic aorta	UBERON:0002345	94.06	gold quality
rectum	UBERON:0001052	94.04	gold quality
tibial nerve	UBERON:0001323	94.04	gold quality
vermiform appendix	UBERON:0001154	94.00	gold quality
lower esophagus mucosa	UBERON:0035834	93.99	gold quality

Single-cell (SCXA)

Detected in 2 experiment(s), a significant marker in 2.

Experiment	Marker?	Max mean expression
E-CURD-112	yes	4.93
E-ANND-3	no	0.00

Regulation

Is transcription factor: no

miRNA regulators (miRDB)

61 targeting DCTD, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-4776-3P	100.00	68.73	1340
HSA-MIR-548C-3P	99.99	74.01	7587
HSA-MIR-511-3P	99.99	68.85	1467
HSA-MIR-12136	99.98	72.81	5713
HSA-MIR-548AJ-3P	99.96	73.38	5345
HSA-MIR-548X-3P	99.96	73.38	5345
HSA-MIR-6755-5P	99.95	65.59	464
HSA-MIR-548J-3P	99.94	72.61	4881
HSA-MIR-548AE-3P	99.93	72.66	4867
HSA-MIR-548AH-3P	99.93	72.54	4872
HSA-MIR-548AM-3P	99.93	72.54	4872
HSA-MIR-548AQ-3P	99.93	72.66	4867
HSA-MIR-652-5P	99.91	67.49	505
HSA-MIR-4302	99.89	67.94	1187
HSA-MIR-548D-3P	99.87	70.67	4362
HSA-MIR-548BB-3P	99.86	70.58	4354
HSA-MIR-548AC	99.84	70.77	4351
HSA-MIR-548H-3P	99.84	70.80	4349
HSA-MIR-548Z	99.84	70.80	4349
HSA-MIR-6875-3P	99.82	70.26	2983
HSA-MIR-6745	99.74	65.33	1321
HSA-MIR-4524A-3P	99.72	66.85	2406
HSA-MIR-548M	99.70	68.87	1749
HSA-MIR-651-5P	99.64	68.49	1104
HSA-MIR-516B-5P	99.56	66.33	1495
HSA-MIR-1252-3P	99.55	67.71	2862
HSA-MIR-6833-5P	99.50	68.93	1161
HSA-MIR-4519	99.48	66.10	859
HSA-MIR-766-5P	99.47	67.91	2225
HSA-MIR-363-5P	99.46	64.51	1015

Cross-species orthologs

5 orthologs

Organism	Symbol	Gene ID
danio_rerio	dctd	ENSDARG00000036990
mus_musculus	Dctd	ENSMUSG00000031562
rattus_norvegicus	Dctd	ENSRNOG00000013215
drosophila_melanogaster	CG6951	FBGN0036959
caenorhabditis_elegans		WBGENE00014034

Paralogs (1): CDADC1 (ENSG00000102543)

Protein

Protein identifiers

Deoxycytidylate deaminase — P32321 (reviewed: P32321)

Alternative names: dCMP deaminase

All UniProt accessions (11): P32321, D6R9P0, D6R9S0, D6RAD7, D6RAR9, D6RBJ9, D6RBN2, D6RC36, D6RD72, D6RIG3, D6RJA9

UniProt curated annotations — full annotation on UniProt →

Function. Catalyzes the deamination of dCMP to dUMP, providing the nucleoside monophosphate substrate for the thymidylate synthase/TYMS. Also, part of a nucleotide salvage pathway that eliminates epigenetically modified 5-hydroxymethyl-dCMP (hmdCMP) in a two-step process entailing deamination to cytotoxic 5-hydroxymethyl-dUMP (hmdUMP), followed by its hydrolysis into 5-hydroxymethyluracil (hmU) and 2-deoxy-D-ribose 5-phosphate (deoxyribosephosphate). Catalyzes the first step in that pathway, the deamination of 5-hydroxymethyl-dCMP (hmdCMP).

Subunit / interactions. Homohexamer.

Activity regulation. Allosteric enzyme whose activity is greatly influenced by the end products of its metabolic pathway, dCTP and dTTP.

Similarity. Belongs to the cytidine and deoxycytidylate deaminase family.

Isoforms (2)

UniProt ID	Names	Canonical?
P32321-1	1	yes
P32321-2	2

RefSeq proteins (9): NP_001012750, NP_001338672, NP_001338673, NP_001338674, NP_001338676, NP_001338677, NP_001338679, NP_001338682, NP_001912* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR002125	CMP_dCMP_dom	Domain
IPR015517	dCMP_deaminase-rel	Family
IPR016192	APOBEC/CMP_deaminase_Zn-bd	Binding_site
IPR016193	Cytidine_deaminase-like	Homologous_superfamily
IPR016473	dCMP_deaminase	Family
IPR035105	Deoxycytidylate_deaminase_dom	Domain

Pfam: PF00383

Catalyzed reactions (Rhea), 2 shown:

• dCMP + H2O + H(+) = dUMP + NH4(+) (RHEA:22924)
• 5-hydroxymethyl-dCMP + H2O + H(+) = 5-hydroxymethyl-dUMP + NH4(+) (RHEA:77175)

UniProt features (25 total): helix 6, strand 6, turn 3, binding site 3, sequence conflict 2, chain 1, domain 1, active site 1, modified residue 1, splice variant 1

Structure

Experimental structures (PDB)

1 structures.

PDB	Method	Resolution (Å)
2W4L	X-RAY DIFFRACTION	2.1

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-P32321-F1	94.43	0.87

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Catalytic / active sites (1): 86 (proton donor)

Ligand- & substrate-binding residues (3): 84; 110; 113

Post-translational modifications (1): 174

Function

Pathways and Gene Ontology

Reactome pathways

1 pathways

ID	Pathway
R-HSA-499943	Interconversion of nucleotide di- and triphosphates

MSigDB gene sets: 165 (showing top): GOBP_ORGANOPHOSPHATE_METABOLIC_PROCESS, MORF_HDAC2, GOBP_NUCLEOSIDE_PHOSPHATE_BIOSYNTHETIC_PROCESS, GOBP_ORGANOPHOSPHATE_BIOSYNTHETIC_PROCESS, GOBP_CARBOHYDRATE_DERIVATIVE_METABOLIC_PROCESS, GOBP_NUCLEOBASE_CONTAINING_SMALL_MOLECULE_METABOLIC_PROCESS, GOBP_SMALL_MOLECULE_BIOSYNTHETIC_PROCESS, KOKKINAKIS_METHIONINE_DEPRIVATION_96HR_UP, GOBP_PYRIMIDINE_NUCLEOTIDE_METABOLIC_PROCESS, GOBP_CARBOHYDRATE_DERIVATIVE_BIOSYNTHETIC_PROCESS, MORF_BUB3, chr4q35, KOKKINAKIS_METHIONINE_DEPRIVATION_48HR_UP, MORF_PRKDC, GOBP_NUCLEOSIDE_SALVAGE

GO Biological Process (5): pyrimidine nucleotide metabolic process (GO:0006220), dUMP biosynthetic process (GO:0006226), dTMP biosynthetic process (GO:0006231), nucleoside salvage (GO:0043174), nucleotide biosynthetic process (GO:0009165)

GO Molecular Function (8): dCMP deaminase activity (GO:0004132), zinc ion binding (GO:0008270), identical protein binding (GO:0042802), 5-hydroxymethyl-dUMP N-hydrolase activity (GO:0070694), catalytic activity (GO:0003824), protein binding (GO:0005515), hydrolase activity (GO:0016787), metal ion binding (GO:0046872)

GO Cellular Component (2): cytoplasm (GO:0005737), cytosol (GO:0005829)

Reactome top-level categories

Rollup of top-1 pathways:

Category	Pathways
Metabolism of nucleotides	1

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
nucleotide metabolic process	2
pyrimidine deoxyribonucleoside monophosphate biosynthetic process	2
pyrimidine deoxyribonucleotide biosynthetic process	2
cellular anatomical structure	2
pyrimidine-containing compound metabolic process	1
dUMP metabolic process	1
dTMP metabolic process	1
nucleoside biosynthetic process	1
metabolic compound salvage	1
nucleoside phosphate biosynthetic process	1
hydrolase activity, acting on carbon-nitrogen (but not peptide) bonds, in cyclic amidines	1
deaminase activity	1
transition metal ion binding	1
protein binding	1
hydrolase activity, hydrolyzing N-glycosyl compounds	1
molecular_function	1
binding	1
catalytic activity	1
cation binding	1
intracellular anatomical structure	1
cytoplasm	1

Protein interactions and networks

STRING

744 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
DCTD	TYMS	P04818	934
DCTD	CDA	P32320	910
DCTD	DCK	P27707	784
DCTD	DTYMK	P23919	704
DCTD	DUT	P33316	695
DCTD	DCTPP1	Q9H773	598
DCTD	SLC29A1	Q99808	594
DCTD	TK2	O00142	591
DCTD	RRM1	P23921	587
DCTD	TK1	P04183	586
DCTD	CTPS1	P17812	566
DCTD	UMPS	P11172	540
DCTD	SLC28A1	O00337	540
DCTD	CTPS2	Q9NRF8	535
DCTD	UPRT	Q96BW1	516

IntAct

60 interactions, top by confidence:

A	B	Type	Score
DCTD	GORASP2	psi-mi:“MI:0915”(physical association)	0.780
DCTD	DCTD	psi-mi:“MI:0915”(physical association)	0.740
DCTD	SDCBP	psi-mi:“MI:0915”(physical association)	0.720
DCTD	MALSU1	psi-mi:“MI:0915”(physical association)	0.720
SDCBP	DCTD	psi-mi:“MI:0915”(physical association)	0.720
MALSU1	DCTD	psi-mi:“MI:0915”(physical association)	0.720
ENPP6	SCAMP1	psi-mi:“MI:0914”(association)	0.640
FGF12	DCTD	psi-mi:“MI:0915”(physical association)	0.560
DCTD	TXN2	psi-mi:“MI:0915”(physical association)	0.560
DCTD	FGF12	psi-mi:“MI:0915”(physical association)	0.560
DCTD	CAF40	psi-mi:“MI:0915”(physical association)	0.560
DCTD	RPC11	psi-mi:“MI:0915”(physical association)	0.560
CAF40	DCTD	psi-mi:“MI:0915”(physical association)	0.560
RPC11	DCTD	psi-mi:“MI:0915”(physical association)	0.560
ACOT7	DCTD	psi-mi:“MI:0915”(physical association)	0.560

BioGRID (43): FGF12 (Two-hybrid), SDCBP (Two-hybrid), TXN2 (Two-hybrid), GORASP2 (Two-hybrid), MALSU1 (Two-hybrid), LNX1 (Two-hybrid), CEP76 (Two-hybrid), NUDT18 (Two-hybrid), NIF3L1 (Two-hybrid), DCTD (Two-hybrid), NGRN (Affinity Capture-MS), DCTD (Two-hybrid), DCTD (Two-hybrid), DCTD (Proximity Label-MS), DCTD (Two-hybrid)

ESM2 similar proteins: B3M383, B3P3W1, B4HLH4, B4JT42, B4K5R2, B4LX81, B4NBB0, B4PRJ9, B5DFN2, F1NTD6, F4KH86, O43865, O65571, O74942, P00814, P06773, P0C1J0, P16006, P30648, P32321, P34401, P38756, P47058, P50245, P87241, Q10003, Q12362, Q1EHT7, Q21407, Q21988, Q296Q5, Q5M9G0, Q5R889, Q5RC69, Q6FPH9, Q6J5K9, Q6NPD7, Q7QCW2, Q7YTB0, Q80SW1

Diamond homologs: O22000, O43012, P00814, P06773, P16006, P30648, P32321, P32393, P33968, P50853, P68397, P68398, Q5M9G0, Q5RC69, Q8FF24, Q8K2D6, Q8XA44, O67050, P21335, P44931, P70814, Q8K9R4, Q99W51, P57343, Q9VWA2, Q4R683, Q5RAX4, Q5U3U4, Q8BMD5, Q9BWV3

SIGNOR signaling

0 interactions.

Disease & clinical

Clinical variants and AI predictions

ClinVar

45 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	0
Uncertain significance	34
Likely benign	3
Benign	2

Top pathogenic / likely-pathogenic (0)

SpliceAI

1146 predictions. Top by Δscore:

Variant	Effect	Δscore
4:182891473:ATTTC:A	acceptor_gain	1.0000
4:182891474:TTTC:T	acceptor_gain	1.0000
4:182891475:TTC:T	acceptor_gain	1.0000
4:182891476:TC:T	acceptor_gain	1.0000
4:182891476:TCCTA:T	acceptor_loss	1.0000
4:182891477:CC:C	acceptor_gain	1.0000
4:182891478:C:CC	acceptor_gain	1.0000
4:182893026:CTTA:C	donor_loss	1.0000
4:182893027:TTAC:T	donor_loss	1.0000
4:182893028:TA:T	donor_loss	1.0000
4:182893029:A:AC	donor_gain	1.0000
4:182893029:ACCG:A	donor_loss	1.0000
4:182893030:C:CC	donor_gain	1.0000
4:182893030:C:G	donor_loss	1.0000
4:182893127:CCTGT:C	acceptor_loss	1.0000
4:182893128:C:T	acceptor_loss	1.0000
4:182893129:T:G	acceptor_loss	1.0000
4:182894544:A:AC	donor_gain	1.0000
4:182894545:C:CC	donor_gain	1.0000
4:182894545:CTA:C	donor_gain	1.0000
4:182894601:GCACA:G	acceptor_gain	1.0000
4:182894602:CACA:C	acceptor_gain	1.0000
4:182894602:CACAC:C	acceptor_gain	1.0000
4:182894603:ACA:A	acceptor_gain	1.0000
4:182894603:ACACT:A	acceptor_loss	1.0000
4:182894604:CA:C	acceptor_gain	1.0000
4:182894604:CAC:C	acceptor_gain	1.0000
4:182894605:ACTGT:A	acceptor_loss	1.0000
4:182894606:C:A	acceptor_loss	1.0000
4:182894606:C:CC	acceptor_gain	1.0000

AlphaMissense

1204 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
4:182915012:C:T	G52E	0.999
4:182915018:C:T	G50E	0.999
4:182894584:G:T	A89D	0.998
4:182894585:C:G	A89P	0.998
4:182915005:A:C	N54K	0.998
4:182915005:A:T	N54K	0.998
4:182915019:C:A	G50W	0.998
4:182915019:C:G	G50R	0.998
4:182915019:C:T	G50R	0.998
4:182915047:G:C	C40W	0.998
4:182915052:C:G	A39P	0.998
4:182915482:T:A	R29S	0.998
4:182915482:T:G	R29S	0.998
4:182915483:C:G	R29T	0.998
4:182915508:C:G	A21P	0.998
4:182894492:C:G	A120P	0.997
4:182894596:G:T	A85E	0.997
4:182894598:A:C	H84Q	0.997
4:182894598:A:T	H84Q	0.997
4:182894600:G:C	H84D	0.997
4:182914933:T:A	K78N	0.997
4:182914933:T:G	K78N	0.997
4:182914966:C:A	W67C	0.997
4:182914966:C:G	W67C	0.997
4:182914968:A:G	W67R	0.997
4:182914968:A:T	W67R	0.997
4:182915490:C:G	A27P	0.997
4:182915501:G:T	A23D	0.997
4:182894509:G:T	A114D	0.996
4:182894510:C:G	A114P	0.996

dbSNP variants (sampled 300 via entrez): RS1000018152 (4:182895766 C>T), RS1000060262 (4:182908055 A>C), RS1000078661 (4:182911692 C>T), RS10001362 (4:182893669 A>C), RS1000205595 (4:182896155 C>A), RS1000235111 (4:182917135 C>T), RS1000392908 (4:182912215 C>T), RS1000406581 (4:182905429 A>T), RS1000482948 (4:182895505 C>A,T), RS1000550525 (4:182889801 C>G), RS1000881314 (4:182891458 T>C), RS1000911713 (4:182900232 C>T), RS10009825 (4:182901439 A>C), RS1001175885 (4:182911782 C>T), RS1001347405 (4:182914545 A>G)

Disease associations

OMIM: gene MIM:607638 | disease phenotypes:

GenCC curated gene-disease

Mondo (0):

Orphanet (0):

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

14 associations (top):

Study	Trait	p-value
GCST001762_295	Obesity-related traits	2.000000e-06
GCST002160_1	Wegener’s granulomatosis	2.000000e-06
GCST002875_137	Diisocyanate-induced asthma	9.000000e-09
GCST009391_1148	Metabolite levels	8.000000e-06
GCST009391_1466	Metabolite levels	6.000000e-06
GCST009391_1473	Metabolite levels	2.000000e-06
GCST009391_1516	Metabolite levels	9.000000e-06
GCST009391_1523	Metabolite levels	5.000000e-06
GCST009391_1948	Metabolite levels	3.000000e-06
GCST009391_2099	Metabolite levels	5.000000e-06
GCST009391_263	Metabolite levels	9.000000e-06
GCST009391_694	Metabolite levels	4.000000e-07
GCST009391_707	Metabolite levels	9.000000e-06
GCST009391_839	Metabolite levels	9.000000e-06

EFO canonical traits (13, from GWAS)

EFO ID	Trait name
EFO:0003939	energy intake
EFO:0006995	response to diisocyanate
EFO:0010457	Alpha ketoglutarate measurement
EFO:0010406	triacylglycerol 48:3 measurement
EFO:0010407	triacylglycerol 48:4 measurement
EFO:0010417	triacylglycerol 52:5 measurement
EFO:0010418	triacylglycerol 52:6 measurement
EFO:0010462	aspartate measurement
EFO:0010374	phosphatidylcholine 32:2 measurement
EFO:0010426	triacylglycerol 54:8 measurement
EFO:0007745	lactate measurement
EFO:0010356	lysophosphatidylcholine 14:0 measurement
EFO:0010399	triacylglycerol 44:1 measurement

Drugs & pharmacology

Drug and pharmacology data

Is drug target: yes

ChEMBL targets (1): CHEMBL5675 (SINGLE PROTEIN)

PharmGKB: 1 entry (VIP=true, CPIC=false)

PharmGKB clinical annotations

1 annotations.

Variant	Type	Level	Drugs	Phenotypes
rs12507552	Efficacy	3	gemcitabine	Pancreatic Neoplasms

PharmGKB variants

3 variants.

Variant	Genes	Level	Score	#Clin annots	Drugs
rs4742	DCTD		0.00	0
rs12507552	DCTD	3	2.75	1	gemcitabine
rs35932500	DCTD		0.00	0

ChEMBL bioactivities

2 potent at pChembl≥5 of 2 total, top 2 by pChembl (potency: 10 = 0.1 nM, 6 = 1 µM).

pChembl	Type	Value	Unit	Molecule
7.37	Kd	42.27	nM	CHEMBL5653589
7.26	ED50	54.7	nM	CHEMBL5653589

PubChem BioAssay actives

1 with measured affinity, of 8 total; 1 most potent distinct compounds. Largely complementary to BindingDB; screening values are coarse (µM, 4 dp), so sub-nM hits tie at the floor.

Compound	Assay	Type	Value	Unit
4-methyl-3-[(2-methyl-6-pyridin-3-ylpyrazolo[3,4-d]pyrimidin-4-yl)amino]-N-[3-(trifluoromethyl)phenyl]benzamide	2148202: Binding affinity to human DCTD incubated for 45 mins by Kinobead based pull down assay	kd	0.0423	uM

CTD chemical–gene interactions

34 total (human), top 30 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
Valproic Acid	affects expression, decreases expression	2
bisphenol F	decreases expression, affects cotreatment	1
alpha phellandrene	decreases expression	1
triphenyl phosphate	affects expression	1
alpha-pinene	affects cotreatment, increases oxidation, increases abundance	1
trichostatin A	affects expression	1
sodium arsenite	decreases expression	1
cobaltous chloride	decreases expression	1
4-aminophenylarsenoxide	affects binding, decreases reaction	1
methacrylaldehyde	affects cotreatment, increases oxidation, increases abundance	1
perfluorooctane sulfonic acid	increases expression	1
CGP 52608	affects binding, increases reaction	1
deguelin	increases expression	1
ICG 001	increases expression	1
bisphenol S	increases expression	1
bisphenol AF	increases expression	1
Temozolomide	decreases expression	1
Sunitinib	increases expression	1
Arsenic Trioxide	decreases reaction, affects binding	1
Acrolein	affects cotreatment, increases oxidation, increases abundance	1
Air Pollutants	affects cotreatment, increases abundance, increases oxidation	1
Antimycin A	decreases expression	1
Dexamethasone	affects cotreatment, decreases expression	1
Enzyme Inhibitors	decreases activity, increases O-linked glycosylation	1
Indomethacin	affects cotreatment, decreases expression	1
Ivermectin	decreases expression	1
Ozone	affects cotreatment, increases oxidation, increases abundance	1
Smoke	decreases expression	1
Tobacco Smoke Pollution	increases expression	1
Tretinoin	decreases expression	1

ChEMBL screening assays

5 unique, capped per target: 5 binding

Representative assays (with source publication via chembl_document):

Assay ID	Type	Description	Source paper
CHEMBL1051088	Binding	Activity of cloned deoxycytidylate deaminase in human HepG2 cells by spectrophotometric analysis	The mechanism of action of beta-D-2’-deoxy-2’-fluoro-2’-C-methylcytidine involves a second metabolic pathway leading to beta-D-2’-deoxy-2’-fluoro-2’-C-methyluridine 5’-triphosphate, a potent inhibitor of the hepatitis C virus RNA-dependent RNA polymerase. — Antimicrob Agents Chemother

Cellosaurus cell lines

1 cell lines: 1 cancer cell line

First 10 cell lines (id-ordered, not curated):

Cellosaurus	Name	Category	Sex
CVCL_XN17	HAP1 DCTD (-)	Cancer cell line	Male

Clinical trials (associated diseases)

0 trials via MONDO — disease-level, not drug-specific.